Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Press release Nanoform Finland Plc January 5, 2023 08:10 Finnish time / 07:10 Swedish time Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD);formulation of nanoenzalutamide and Xtandi[®[1]], the number one prescribed androgen receptor